Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PARADI MIRMIRANI

Allopathic & Osteopathic Physicians Dermatology

NPI
1780758086
CMS profile
528173
Location
VALLEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,190.07

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $891.86 4
Food and Beverage $298.21 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $1,190.07 6

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PARADI MIRMIRANI

NPI 1780758086 · CMS profile ID 528173

Allopathic & Osteopathic Physicians / Dermatology

VALLEJO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780758086?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780758086?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780758086?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PARADI MIRMIRANI, NPI 1780758086, CMS profile ID 528173, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1780758086?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $1,190.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.4708/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673732517 CMS
PFIZER INC. $88.9305/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673287341 CMS
PFIZER INC. $311.2704/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673285975 CMS
PFIZER INC. $290.9604/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673288815 CMS
PFIZER INC. $277.7404/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673290059 CMS
PFIZER INC. $200.7004/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673734975 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,190.07 6
PY2021 $5,100.00 1
PY2022 $3,726.42 4
PY2024 $5,123.32 3
PY2025 $16,185.62 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $479,737.84 282
PY2024 Recipient $3,200.00 1
PY2024 Principal investigator $768,360.94 287
PY2023 Recipient $5,740.00 5
PY2023 Principal investigator $318,195.33 82
PY2022 Recipient $1,600.00 3
PY2022 Principal investigator $29,594.10 8
PY2021 Principal investigator $84,014.35 20
PY2020 Principal investigator $176,397.66 37
PY2019 Principal investigator $77,460.50 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient PFIZER INC. $3,200.00 12/20/2023 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046384329
Principal investigator 1 PFIZER INC. $403.92 12/18/2023 Non-covered Recipient Entity
Kaiser Permanente
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1046415247
Principal investigator 1 PFIZER INC. $1,047.60 12/18/2023 Non-covered Recipient Entity
Kaiser Permanente
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1046415471
Principal investigator 1 Amgen Inc. $4,724.16 11/17/2023 Covered Recipient Teaching Hospital
KFH - SAN FRANCISCO
P3 AD Adult Combo TCS No dispute reported 06/30/2026 1029654035
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,724.00 11/07/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791251
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $22,116.51 10/27/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791191
Principal investigator 1 Amgen Inc. $5,511.52 10/25/2023 Covered Recipient Teaching Hospital
KFH - OAKLAND
P3 AD Adult Combo TCS No dispute reported 06/30/2026 1029654029
Recipient PFIZER INC. $940.00 10/11/2023 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046380311
Principal investigator 1 PFIZER INC. $2,446.60 10/11/2023 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1046391221
Principal investigator 1 PFIZER INC. $2,627.30 09/01/2023 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1046371839
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $14,600.00 08/09/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791103
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $25,914.33 07/14/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791215
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $25,079.40 07/14/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791227
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,891.80 06/09/2023 Non-covered Recipient Entity
Kaiser
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053791331
Principal investigator 1 PFIZER INC. $16,815.00 06/01/2023 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1046497507
Principal investigator 1 PFIZER INC. $2,605.20 05/24/2023 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1046536873
Recipient PFIZER INC. $330.00 05/18/2023 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046412971
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,016.60 05/11/2023 Non-covered Recipient Entity
Kaiser
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053791313
Recipient PFIZER INC. $940.00 05/10/2023 Covered Recipient Physician RITLECITINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046411457
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $29,536.20 04/20/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791155
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $21,697.65 04/11/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791141
Principal investigator 1 Incyte Corporation $21.44 03/11/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834945
Principal investigator 1 Incyte Corporation $90.00 03/11/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834957
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834750
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834763
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834775
Principal investigator 1 Incyte Corporation $979.71 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834811
Principal investigator 1 Incyte Corporation $35.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834885
Principal investigator 1 Incyte Corporation $50.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834897
Principal investigator 1 Incyte Corporation $11.96 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834933
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834985
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835071
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835083
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835101
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835113
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835197
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835211
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835223
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835235
Principal investigator 1 Incyte Corporation $979.71 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835249
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835335
Principal investigator 1 Incyte Corporation $30.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835347
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835359
Principal investigator 1 Incyte Corporation $60.00 03/10/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835371
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834701
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834713
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834725
Principal investigator 1 Incyte Corporation $139.99 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834737
Principal investigator 1 Incyte Corporation $653.14 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834787
Principal investigator 1 Incyte Corporation $12.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834861
Principal investigator 1 Incyte Corporation $45.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834873
Principal investigator 1 Incyte Corporation $10.92 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834909
Principal investigator 1 Incyte Corporation $14.68 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834921
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834975
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835009
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835023
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835035
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835047
Principal investigator 1 Incyte Corporation $139.99 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835059
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835137
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835151
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835163
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835175
Principal investigator 1 Incyte Corporation $139.99 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835187
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835273
Principal investigator 1 Incyte Corporation $30.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835287
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835299
Principal investigator 1 Incyte Corporation $60.00 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835311
Principal investigator 1 Incyte Corporation $139.99 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835321
Principal investigator 1 Incyte Corporation $653.14 03/09/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835383
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $8,235.00 03/09/2023 Non-covered Recipient Entity
Kaiser
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053791301
Principal investigator 1 Incyte Corporation $768.81 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834675
Principal investigator 1 Incyte Corporation $143.19 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834687
Principal investigator 1 Incyte Corporation $783.52 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834799
Principal investigator 1 Incyte Corporation $1,209.42 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834823
Principal investigator 1 Incyte Corporation $918.52 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834837
Principal investigator 1 Incyte Corporation $50.00 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834849
Principal investigator 1 Incyte Corporation $143.19 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040834997
Principal investigator 1 Incyte Corporation $143.19 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835123
Principal investigator 1 Incyte Corporation $143.19 03/08/2023 Non-covered Recipient Entity
KAISER PERMANENTE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1040835261
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $16,722.00 02/22/2023 Non-covered Recipient Entity
Kaiser
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053791289
Principal investigator 1 PFIZER INC. $2,627.30 02/14/2023 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1046449719
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,080.10 02/10/2023 Non-covered Recipient Entity
Kaiser
A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata No dispute reported 06/30/2026 1053791277
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $27,439.20 01/31/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791129
Principal investigator 1 PFIZER INC. $1,400.10 01/27/2023 Covered Recipient Teaching Hospital
KFH - ANTIOCH
A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA No dispute reported 06/30/2026 1046544815
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $28,074.15 01/27/2023 Non-covered Recipient Entity
Kaiser
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1053791169
Recipient PFIZER INC. $330.00 01/13/2023 Covered Recipient Physician LITFULO CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1046529243